Phathom Pharmaceuticals (NASDAQ:PHAT) versus Neuphoria Therapeutics (NASDAQ:NEUP) Head-To-Head Review

Phathom Pharmaceuticals (NASDAQ:PHAT) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Risk & Volatility

Phathom Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Insider & Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 23.0% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Phathom Pharmaceuticals and Neuphoria Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1	1	6	1	2.78
Neuphoria Therapeutics	1	1	2	0	2.25

Phathom Pharmaceuticals currently has a consensus target price of $22.50, suggesting a potential upside of 75.92%. Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 351.61%. Given Neuphoria Therapeutics’ higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Phathom Pharmaceuticals.

Profitability

This table compares Phathom Pharmaceuticals and Neuphoria Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-126.35%	N/A	-68.66%
Neuphoria Therapeutics	N/A	-25.98%	-18.39%

Earnings and Valuation

This table compares Phathom Pharmaceuticals and Neuphoria Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11 million	5.80	-$221.25 million	($3.06)	-4.18
Neuphoria Therapeutics	$14.99 million	1.67	-$370,000.00	($4.42)	-1.05

Neuphoria Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Phathom Pharmaceuticals beats Neuphoria Therapeutics on 10 of the 15 factors compared between the two stocks.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.